Stroke Drug Development Targeting Caveolin-1

Caveolin-1 (Cav-1), a major scaffolding protein for membrane lipid rafts (MLR), targets many nerve growth proteins and promotes neuronal and dendritic growth, suggesting that targeting Cav-1 to enhance post-ischemic neuroplasticity is a potential therapeutic avenue for stroke. In response to the role of Cav-1 in stroke pathology, Ace Therapeutics offers comprehensive services to develop new stroke drugs targeting Cav-1. In both ischemic and hemorrhagic stroke, Cav-1 can regulate stroke pathology through modulation of oxidative stress, inflammatory response, and blood brain barrier permeability. We offer comprehensive services to develop new stroke drugs targeting Cav-1. With our advanced technology and quality service, we ensure that your research runs smoothly.

High Throughput Screening of Cav-1 Regulator

Ischemic stroke and hemorrhagic stroke can have different effects on the body. However, studies have demonstrated that regulation of Cav-1 activity is effective in alleviating the injury caused by stroke. Therefore, for ischemic and hemorrhagic strokes, Ace Therapeutics offers different services to target Cav-1 for stroke drug development.

For ischemic stroke and hemorrhagic stroke, we provide different in vitro and in vivo models to cover different pathological conditions of stroke onset.
For Cav-1-mediated stroke pathological processes, such as neuroinflammation, oxidative stress, and other responses, we offer gene microarray technology and protein microarray technology for high-throughput screening of Cav-1-mediated differential genes and proteins that regulate stroke processes.
Targeting Cav-1 and differential genes and proteins, based on our drug screening platform, we implement high-throughput screening of candidate Cav-1 modulators to increase the success rate of drug screening.
We provide different in vitro models for preliminary validation of the effects of candidate modulators on stroke.

Preclinical Evaluation of Drug Candidates for the Treatment of Stroke

After the initial determination of the therapeutic effect of a drug candidate on stroke, Ace Therapeutics provides quality services to fully evaluate the specific mechanism of action of the drug candidate on stroke. Our services cover all aspects of the study, and we will support your study with care and professionalism.

We have established different in vitro and in vivo stroke models to validate the therapeutic effect of Cav-1 regulator on stroke and to further explore the mechanism of Cav-1 action.
To evaluate the effect of drug candidates on recovery from post-stroke brain injury, we have established well-established protocols to score and detect brain injury.
For Cav-1 downstream genes or proteins, we provide different expression level assays and localization services to further explore the role of drug candidates in stroke development.

In addition, we provide you with customized research service solutions based on your research needs. If you would like to learn more about our services, please feel free to contact us.

Reference

Chang, C. F., et al., Caveolin-1 deletion reduces early brain injury after experimental intracerebral hemorrhage. Am J Pathol, 2011. 178(4): p. 1749-176

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.